Deutsche Bank downgraded Avanir Pharmaceuticals (NASDAQ: AVNR) from Buy to Hold with a price target of $17.00.Analyst Alethia Young said ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE